No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
336 |
4. Check minimum number of eventsNone |
336 |
5. Include endpointsNone |
336 |
6. Filter based on genotype QC (FinnGen only) |
320 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia [CML], BCR/ABL-positive
based on the number of shared cases.
Similar with more cases:
- Myeloid leukaemia
- Myeloproliferative diseases
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2730 | 1222 | 1459 |
| Only index persons | 1748 | 801 | 947 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 61.57 | 61.90 | 61.03 |
| Only index persons | 59.17 | 59.30 | 59.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 320 | 146 | 174 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.08 |
| Median age at first event (years) | 60.54 | 57.64 | 62.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 336
- Matched controls
- 3360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
307.7
334
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
320.4
307.7
297
78
XW000
NOMESCO Finland
Bone marrow biopsy
56.1
286.1
184
71
189
Kela drug reimbursment
Imatinib
4143.0
217.5
186
*
L01XE01
ATC
[U] imatinib
2853.6
176.4
155
*
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
153.2
135
*
M04AA01
ATC
allopurinol; systemic
13.8
134.7
187
281
L01EA01
ATC
imatinib; oral
920.0
130.9
120
*
316
Kela drug reimbursment
Imatinib
+∞
111.9
101
*
L01XX05
ATC
hydroxycarbamide; oral
1334.3
104.0
96
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
39.8
76.9
48
14
127
Kela drug reimbursment
Transplant complication
35.4
71.3
46
15
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
176.0
68.9
70
5
152
Kela drug reimbursment
Nilotinib
+∞
64.7
60
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
119.1
63.6
67
7
212
Kela drug reimbursment
Gout
22.2
62.6
48
25
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.4
50.4
106
227
L01XX28
ATC
[U] imatinib
+∞
50.3
47
*
150
Kela drug reimbursment
Dasatinib
+∞
48.1
45
*
328
Kela drug reimbursment
Nilotinib
+∞
41.5
39
*
L01XE08
ATC
[U] nilotinib
+∞
41.5
39
*
L01XE06
ATC
[U] dasatinib
+∞
41.5
39
*
L03AA02
ATC
filgrastim; parenteral
10.2
39.9
48
54
L01EA03
ATC
nilotinib; oral
+∞
38.3
36
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.4
29.4
53
95
324
Kela drug reimbursment
Dasatinib
+∞
26.4
25
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
9.0
25.7
33
40
R50.9
ICD-10 Finland
Fever, unspecified
3.9
25.4
92
293
WW500
NOMESCO Finland
Blood transfusion
6.6
24.5
42
71
WW200
NOMESCO Finland
Immunization
10.1
23.9
28
30
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
7.8
23.3
34
48
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
22.1
21
*
L01EA02
ATC
dasatinib; oral
+∞
21.1
20
*
L04AA01
ATC
[U] ciclosporin
31.2
20.0
26
9
A05AA02
ATC
ursodeoxycholic acid; oral
18.5
19.1
29
17
170
Kela drug reimbursment
Bosutinib
+∞
18.9
18
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
18.9
18
*
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
100.4
17.7
19
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
189.6
17.7
18
*
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
189.6
17.7
18
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
17.6
197
1155
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
44.7
17.5
21
5
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
66.9
16.9
19
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
37.2
16.9
21
6
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
16.8
16
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.0
16.3
37
81
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
22.3
16.2
23
11
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.3
15.8
68
238
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
33.4
15.0
19
6
360
Kela drug reimbursment
Bosutinib
+∞
14.7
14
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
11.2
14.0
26
25
L03AB05
ATC
interferon alfa-2b; parenteral
41.9
13.3
16
*
L01EA04
ATC
bosutinib; oral
+∞
12.6
12
*
B73
ICPC
Leukaemia
134.8
12.5
13
*
C03CA01
ATC
furosemide; systemic
2.3
12.1
131
724
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
31.3
11.7
15
5
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
11.5
11
*
B03XA02
ATC
darbepoetin alfa; parenteral
8.5
11.3
24
30
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
20.9
11.2
16
8
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.9
11.2
35
98
J01MA14
ATC
moxifloxacin; systemic
3.2
11.2
48
166
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
18.6
10.8
16
9
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.2
10.8
45
153
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
10.5
10
*
L01XE14
ATC
[U] bosutinib
+∞
10.5
10
*
L04AD01
ATC
ciclosporin; systemic
11.8
10.2
18
16
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.5
10.2
76
353
J05AB11
ATC
valaciclovir; oral
2.6
10.1
70
313
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
41.4
10.0
12
*
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
26.9
9.9
13
5
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
20.8
9.9
14
7
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.8
9.8
53
209
B03XA01
ATC
erythropoietin; parenteral
15.6
9.6
15
10
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
102.8
9.5
10
*
A01AB04
ATC
amphotericin B; local oral
3.7
9.2
30
87
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.1
9.1
26
68
A04AA01
ATC
ondansetron; systemic, rectal
3.1
9.0
40
141
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
19.2
9.0
13
7
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.8
8.8
47
184
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
16.8
8.6
13
8
J02AC03
ATC
voriconazole; systemic
28.3
8.5
11
*
D64.9
ICD-10 Finland
Anaemia, unspecified
2.7
8.4
50
207
373
Kela drug reimbursment
Ponatinib
+∞
8.4
8
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
+∞
8.4
8
*
D75.2
ICD-10 Finland
Essential thrombocytosis
+∞
8.4
8
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
8.4
8
*
C82.1
ICD-10 Finland
Follicular lymphoma grade II
17.7
8.1
12
7
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.1
8.1
36
127
L03AA04, ,
ATC
22.7
8.1
11
5
A41.9
ICD-10 Finland
Sepsis, unspecified
4.0
7.4
21
55
1529, ,
Kela drug reimbursment
+∞
7.3
7
*
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
7.3
7
*
A07AA02
ATC
nystatin; oral
3.2
7.3
30
101
J01MA12
ATC
levofloxacin; systemic
2.1
7.2
76
404
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
10.3
7.1
13
13
J05AB01
ATC
aciclovir; systemic
2.1
7.0
82
455
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
17.1
6.8
10
6
H02AB04
ATC
methylprednisolone; systemic
2.2
6.7
59
291
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
23.0
6.7
9
*
306
Kela drug reimbursment
Erythropoietin and darbepoetin
23.0
6.7
9
*
N02AA05
ATC
oxycodone; systemic
2.1
6.5
75
411
C93.1
ICD-10 Finland
Chronic myelomonocytic leukaemia
71.1
6.4
7
*
9945/3-C42.1
ICD-O-3
Chronic myelomonocytic leukemia, NOS, of bone marrow
71.1
6.4
7
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
6.3
98
597
C95.1
ICD-10 Finland
Chronic leukaemia of unspecified cell type
+∞
6.3
6
*
C92.2
ICD-10 Finland
Atypical chronic myeloid leukaemia, BCR/ABL- negative
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
L01BB02
ATC
mercaptopurine; oral
10.3
6.1
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
104
49
30.29
145.30
2.3
1.8
—
—
—
0
0
152
227
11.40
107.27
4.4
2.7
69.50
68.57
e9/l
0.10
117
177
93
0
+∞
102.46
15.2
0.0
—
—
—
0
0
89
0
+∞
97.80
11.5
0.0
—
—
—
0
0
169
321
9.58
96.40
5.2
2.6
1.82
1.77
%
0.24
163
295
194
734
4.89
46.29
6.4
2.8
337.12
8431.87
umol/l
3.74
187
635
280
1577
5.65
36.04
28.2
9.3
3.87
4.12
e9/l
0.46
267
1385
45
56
9.12
34.56
9.6
8.7
181.10
135.00
iu/ml
—
10
10
264
1462
4.76
33.64
17.0
6.5
11.42
11.34
umol/l
0.03
259
1380
61
123
5.84
29.96
1.8
1.8
1.27
1.51
g/l
1.04
54
107
38
48
8.80
28.71
1.1
1.4
137.60
91.56
u/ml
—
10
9
244
1368
3.86
28.32
14.7
7.0
1.21
1.21
mmol/l
0.42
216
1171
32
34
10.30
27.50
2.2
2.0
33.47
33.12
pg
0.17
32
34
44
74
6.69
25.83
1.7
1.6
—
—
—
0
0
28
5
60.82
24.43
6.4
1.6
43.93
38.80
u/l
—
28
5
221
1251
3.24
23.40
13.3
5.9
1.21
1.21
mmol/l
0.36
213
1135
34
48
7.77
23.34
2.4
1.9
—
—
—
0
0
34
48
7.77
23.34
2.4
1.9
—
—
—
0
0
31
44
7.66
21.14
6.6
3.9
53.19
57.64
%
0.84
31
44
28
42
7.18
18.14
6.5
3.7
3.04
4.66
e9/l
2.80
28
42
24
31
8.26
17.64
1.6
1.8
—
—
—
0
0
24
31
8.26
17.64
1.6
1.8
—
—
—
0
0
36
72
5.48
17.57
2.7
1.8
—
—
—
0
0
36
73
5.40
17.31
2.5
1.9
—
—
—
0
0
96
396
2.99
16.92
3.2
2.3
22.56
22.25
%
0.08
84
340
22
11
21.30
15.31
1.7
1.5
—
—
—
0
0
241
1635
2.68
14.93
8.1
4.7
6.74
6.75
mmol/l
0.01
233
1537
154
880
2.38
13.48
3.3
2.6
57.95
62.17
u/l
0.33
149
811
28
59
5.09
12.85
1.1
1.2
—
—
—
0
0
95
444
2.59
12.79
2.8
2.0
—
—
—
0
0
126
672
2.40
12.75
2.8
2.0
2.81
3.13
mg/l
0.86
116
575
176
1100
2.26
12.09
4.2
2.6
262.12
150.56
ug/l
2.56
171
1007
26
56
4.95
11.62
2.8
1.9
—
—
—
0
0
20
19
11.11
10.92
4.1
3.3
—
—
—
0
0
25
55
4.83
10.90
1.1
1.2
352.11
288.67
u/ml
0.34
19
33
160
1007
2.12
10.31
4.2
3.2
—
—
—
0
0
21
25
8.88
10.21
1.0
1.1
—
—
—
0
0
70
319
2.51
9.71
2.4
2.0
—
—
—
0
0
29
79
3.92
9.66
1.8
1.2
—
—
—
0
0
51
201
2.81
9.42
2.0
1.5
—
—
—
0
0
23
54
4.50
9.27
1.8
1.7
—
—
—
0
0
69
319
2.46
9.25
2.4
2.0
—
—
—
0
0
32
100
3.43
8.74
2.3
3.0
—
—
—
0
0
190
1326
2.00
8.74
12.5
14.0
1.19
1.29
inr
0.87
56
389
20
44
4.77
8.71
1.6
1.8
—
—
—
0
0
184
1281
1.96
8.40
5.3
2.6
—
—
—
0
0
18
38
4.95
8.21
3.1
1.9
—
—
—
0
0
141
918
1.92
7.66
6.4
3.4
40.35
34.27
u/l
0.44
135
874
26
79
3.48
7.41
1.4
1.2
—
—
—
0
0
99
577
2.01
7.38
1.9
1.7
1.56
1.29
mg/l
0.41
81
439
19
46
4.32
7.37
2.0
1.8
—
—
—
0
0
33
121
2.92
6.93
2.6
2.1
1.86
4.46
ug/l
0.48
33
109
18
34
5.53
6.56
3.0
2.0
—
—
—
0
0
14
20
7.25
6.28
1.0
1.2
—
—
—
0
0
16
29
5.74
6.07
3.2
1.8
—
—
—
0
0
16
29
5.74
6.07
3.3
1.8
—
—
—
0
0
16
29
5.74
6.07
3.2
1.8
—
—
—
0
0
16
40
4.15
5.96
1.9
1.9
—
—
—
0
0
105
676
1.80
5.57
1.9
1.6
19.67
20.57
nmol/l
0.27
95
575
60
321
2.06
5.54
9.6
7.3
12.23
11.99
kpa
0.15
55
309
14
25
5.79
5.43
3.1
2.2
—
—
—
0
0
13
22
6.10
5.27
1.0
1.0
—
—
—
0
0
87
538
1.83
5.23
1.8
1.7
1250.99
1174.09
nmol/l
0.32
80
399
37
167
2.37
5.17
1.9
1.8
—
—
—
0
0
59
325
1.99
5.01
9.7
7.3
1.13
1.18
mmol/l
0.03
43
267
13
24
5.59
4.96
3.1
3.4
40.14
40.79
%
—
7
14
100
658
1.74
4.84
5.8
2.3
—
—
—
0
0
15
43
3.60
4.67
2.0
1.8
—
—
—
0
0
152
1132
1.63
4.53
2.3
2.0
92.38
95.57
pmol/l
0.35
105
587
14
32
4.52
4.49
1.5
1.8
—
—
—
0
0
11
19
5.95
4.48
1.6
1.6
—
—
—
0
0
11
19
5.95
4.48
1.6
1.6
—
—
—
0
0
10
16
6.40
4.32
1.8
2.8
—
—
—
0
0
38
188
2.15
4.29
4.3
2.8
0.46
1.56
mmol/l
0.79
26
138
12
26
4.75
4.09
1.8
1.3
20620.50
46366.29
e6/l
—
6
17
119
851
1.62
4.09
4.7
3.2
678.66
140.07
e6/l
0.39
102
655
14
36
4.01
4.04
1.9
1.9
—
—
—
0
0
9
14
6.57
4.01
4.4
1.9
—
—
—
0
0
9
14
6.57
4.01
4.4
1.9
—
—
—
0
0
10
18
5.69
4.00
4.2
1.8
—
—
—
0
0
10
18
5.69
4.00
4.2
1.8
—
—
—
0
0
9
15
6.13
3.84
1.9
1.3
—
—
—
0
0
9
15
6.13
3.84
1.9
1.3
—
—
—
0
0
9
15
6.13
3.84
4.3
1.9
—
—
—
0
0
19
72
2.74
3.80
1.9
1.5
—
—
—
0
0
7
8
8.90
3.79
1.0
1.0
—
—
—
0
0
26
116
2.35
3.75
1.5
2.7
—
—
—
0
0
16
56
2.95
3.68
1.8
2.4
129.40
129.55
g/l
—
10
40
143
1099
1.52
3.47
3.7
3.7
24.14
41.42
ng/l
2.25
118
799
238
2040
1.57
3.46
6.0
4.1
13.76
12.10
mm/h
0.99
230
1861
34
178
2.01
3.33
1.6
1.5
—
—
—
0
0
6
7
8.70
3.27
1.7
1.3
—
—
—
0
0
8
15
5.43
3.21
2.0
1.3
—
—
—
0
0
8
15
5.43
3.21
2.0
1.3
—
—
—
0
0
7
11
6.47
3.20
7.6
1.4
—
—
—
0
0
19
79
2.49
3.20
1.6
1.5
226.50
301.42
ug/g
0.78
12
48
75
507
1.62
3.16
4.1
3.0
2.45
2.45
mmol/l
0.09
75
450
21
93
2.34
3.10
1.4
4.2
—
2.65
—
0
10
22
100
2.28
3.07
4.0
2.0
—
—
—
0
0
43
252
1.81
3.03
5.5
4.0
2.43
2.00
mmol/l
0.23
36
205
105
781
1.50
2.88
4.4
3.1
0.67
0.50
e6/l
0.26
91
583
7
15
4.74
2.61
1.4
1.1
—
—
—
0
0
6
11
5.53
2.55
1.0
1.1
—
—
—
0
0
24
123
2.02
2.52
5.4
3.0
24.43
24.74
mmol/l
0.17
24
118
20
97
2.13
2.42
2.3
1.8
—
—
—
0
0
9
27
3.40
2.41
1.0
1.8
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
8
6.32
2.38
1.2
1.0
109.00
167.25
%
—
5
8
11
39
2.88
2.36
1.1
1.4
—
—
—
0
0
20
99
2.08
2.31
1.4
1.8
—
123.33
—
0
6
17
80
2.18
2.22
2.3
1.5
—
—
—
0
0
8
24
3.39
2.19
1.1
2.8
—
—
—
0
0
6
14
4.34
2.16
1.7
1.9
991.67
996.29
u/ml
—
6
14
12
49
2.50
2.13
1.5
2.1
59331.60
5369.41
u/l
—
5
19
71
517
1.47
2.12
5.9
3.6
128.85
202.56
ng/l
0.36
61
408
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
82
2.13
2.10
2.9
2.1
0.34
0.40
u/ml
0.22
12
38
11
43
2.61
2.10
1.2
1.0
—
—
—
0
0
64
460
1.48
2.03
4.5
2.9
2.32
1.89
e6/l
0.20
41
257
5
11
4.60
1.95
17.4
3.5
189.60
200.73
u/l
—
5
11
34
213
1.66
1.94
3.9
2.9
57.24
62.73
ml/min/173m2
0.53
21
92
223
1991
1.36
1.88
4.1
3.7
15.15
14.84
pmol/l
0.97
215
1779
12
54
2.27
1.76
1.3
1.5
—
—
—
0
0
12
54
2.27
1.76
1.3
1.5
—
—
—
0
0
157
1342
1.32
1.73
3.7
3.7
0.00
0.00
estimate
-0.00
28
246
5
13
3.89
1.72
3.4
1.5
—
—
—
0
0
5
14
3.61
1.62
1.4
1.3
—
—
—
0
0
10
43
2.37
1.60
2.3
1.5
—
—
—
0
0
154
1325
1.30
1.58
4.7
5.1
0.00
0.00
estimate
-0.00
33
253
10
44
2.31
1.57
2.3
1.5
—
—
—
0
0
10
44
2.31
1.57
2.3
1.5
—
—
—
0
0
10
44
2.31
1.57
2.3
1.5
—
—
—
0
0
10
44
2.31
1.57
2.3
1.5
—
—
—
0
0
14
71
2.01
1.56
2.1
1.4
—
—
—
0
0
13
64
2.07
1.56
1.8
1.3
—
—
—
0
0
15
79
1.94
1.52
1.3
1.4
—
—
—
0
0
10
45
2.26
1.48
2.3
1.5
—
—
—
0
0
11
53
2.11
1.40
1.2
1.5
—
—
—
0
0
289
2732
1.41
1.40
35.7
14.6
20.47
24.53
mg/l
1.29
264
2162
6
23
2.64
1.37
1.0
1.2
—
—
—
0
0
180
1602
1.27
1.35
2.6
2.8
—
—
—
0
0
89
731
1.30
1.26
4.0
3.9
0.00
0.00
estimate
-0.00
28
248
6
25
2.42
1.25
1.0
1.1
—
—
—
0
0
151
1329
1.25
1.20
3.6
3.7
0.00
0.00
estimate
0.50
32
275
73
590
1.30
1.17
3.8
3.8
1.01
1.02
kg/l
2.18
13
83
61
487
1.31
1.07
3.8
2.7
1.48
1.05
e6/l
0.51
40
281
5
22
2.29
1.03
2.2
1.6
0.26
0.21
nmol/l
—
5
16
20
132
1.55
0.99
2.6
2.6
0.65
0.68
%
0.28
20
132
5
23
2.19
0.98
1.0
1.3
—
—
—
0
0
6
27
2.24
0.94
1.7
1.4
—
—
—
0
0
6
28
2.16
0.92
1.7
1.2
—
—
—
0
0
8
42
1.93
0.89
2.4
2.8
106.00
105.40
mmol/l
—
8
42
100
869
1.21
0.86
4.1
3.9
18.85
9.55
mg/mmol
0.68
64
559
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.0
2.0
14.53
17.14
ug/l
—
6
33
6
33
1.83
0.79
2.0
2.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
36
280
1.32
0.78
3.9
3.3
—
—
—
0
0
19
133
1.45
0.75
1.2
1.3
—
—
—
0
0
67
568
1.22
0.74
1.5
1.8
538.36
12364863.28
pmol/l
0.50
53
461
117
1046
1.18
0.73
3.8
3.8
—
—
—
0
0
5
25
2.01
0.73
1.2
3.1
19.60
59.63
u/ml
—
5
25
13
84
1.57
0.73
2.2
1.7
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
28
1.80
0.66
1.8
3.2
1.32
4.26
nmol/l
—
5
28
246
2347
1.18
0.65
46.0
17.6
14.98
15.11
%
0.25
246
2316
8
130
0.61
0.65
1.0
1.0
—
—
—
0
0
41
335
1.25
0.63
10.3
7.2
—
—
—
0
0
13
88
1.50
0.61
1.2
1.2
—
—
—
0
0
11
72
1.55
0.60
2.8
1.8
174.91
240.92
pmol/l
1.56
11
65
295
3022
0.80
0.59
53.2
21.2
4.06
4.51
e12/l
25.29
289
2935
13
89
1.48
0.59
1.2
1.2
—
—
—
0
0
295
3020
0.81
0.57
53.3
21.2
223.72
243.61
e9/l
4.17
290
2941
295
3019
0.81
0.56
53.8
21.3
37.36
40.37
%
12.71
276
2830
254
2443
1.16
0.55
5.2
4.5
1.89
1.94
mu/l
0.26
245
2211
51
441
1.18
0.48
1.2
1.3
1.19
14.29
u/ml
2.79
19
167
8
59
1.36
0.41
1.4
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
2.7
—
—
—
0
0
0
17
0.00
0.41
0.0
2.7
—
—
—
0
0
5
34
1.48
0.40
1.0
1.3
—
—
—
0
0
7
103
0.67
0.40
2.3
2.0
—
—
—
0
0
57
637
0.87
0.38
2.4
3.0
0.70
0.80
ug/l
0.48
36
423
18
224
0.79
0.38
1.7
1.7
—
—
—
0
0
267
2600
1.13
0.38
5.0
4.0
1.60
1.30
mmol/l
1.48
258
2378
6
43
1.40
0.35
1.2
1.2
—
—
—
0
0
81
878
0.90
0.34
3.6
4.2
23.15
21.51
%
0.42
41
410
79
726
1.12
0.34
1.7
1.6
2.03
1.37
mmol/l
1.04
70
608
6
46
1.31
0.33
1.2
1.6
—
—
—
0
0
16
197
0.80
0.32
1.4
1.9
—
—
—
0
0
52
469
1.13
0.30
1.2
1.3
16.45
39.75
iu/ml
2.70
17
153
18
217
0.82
0.30
1.5
2.1
—
—
—
0
0
5
40
1.25
0.22
2.8
3.9
—
—
—
0
0
5
40
1.25
0.22
1.4
1.2
—
1.10
—
0
10
263
2582
1.09
0.22
31.2
13.8
74.25
80.13
ml/min/173m2
3.72
241
2131
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
9.06
—
0
13
15
127
1.19
0.20
1.6
2.9
29.33
69.43
u/ml
0.66
15
122
190
1850
1.06
0.19
3.4
3.2
63.37
50.43
u/l
0.79
179
1727
272
2750
0.94
0.13
5.6
5.0
2.48
2.73
mmol/l
4.94
264
2528
10
87
1.15
0.09
1.9
2.7
—
—
—
0
0
263
2653
0.96
0.08
5.4
4.6
6.11
6.00
mmol/l
0.79
248
2417
55
571
0.96
0.08
1.2
1.2
0.98
1.40
u/ml
—
9
156
7
64
1.10
0.08
1.1
1.2
—
1.08
—
0
5
270
2681
1.04
0.06
5.1
4.4
1.31
1.45
mmol/l
6.16
263
2469
257
2551
1.03
0.06
6.2
5.9
39.04
40.34
mmol/mol
1.89
245
2372
271
2693
1.03
0.06
5.4
4.5
4.32
4.62
mmol/l
4.97
266
2490
36
351
1.03
0.02
1.4
1.9
1.50
1.52
%
0.10
29
314
43
424
1.02
0.00
1.6
1.4
—
—
—
0
0
110
1098
1.00
0.00
4.4
4.9
6.78
2.60
ug/l
0.38
102
974
32
321
1.00
0.00
1.6
1.4
—
—
—
0
0
6
63
0.95
0.00
1.2
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1350.83
—
0
6
7
73
0.96
-0.00
1.1
1.2
—
2.78
—
0
11
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
16
160
1.00
-0.00
1.2
1.3
30.65
148.55
iu/ml
—
6
57
8
80
1.00
-0.00
2.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
-0.00
1.0
1.2
—
—
—
0
0
6
60
1.00
-0.00
1.0
1.2
—
46.58
—
0
6
7
71
0.99
-0.00
1.1
1.2
—
—
—
0
0
5
56
0.89
-0.00
1.2
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
8.01
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
75
0.93
-0.00
1.1
1.2
—
8.38
—
0
13
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
-0.00
1.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CML and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 4.426 [3.35, 5.85] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.636 |
During the follow-up period (1.1.1998 — 31.12.2019), 322 out of 808 females with CML died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 3.628 [2.8, 4.71] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 423 out of 944 males with CML died.
Mortality risk
Mortality risk for people of age
years, who have CML.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.525% | 0.565% |
| 5 | 2.993% | 4.051% |
| 10 | 7.101% | 9.458% |
| 15 | 13.164% | 18.283% |
| 20 | 22.051% | 29.576% |
Relationships between endpoints
↥Index endpoint: CML – Chronic myeloid leukaemia [CML], BCR/ABL-positive
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data